Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis––experiences from recent clinical trials

References

• Pasteur MC, Bilton D, Hill AT, et al. British thoracic society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):i1–58.
   PubMed Web of Science ®Google Scholar
• Aliberti S, Lonni S, Dore S, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J. 2016;47:1113–1122.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45:1446–1462.
   PubMed Web of Science ®Google Scholar
• Munro NC, Han LY, Currie DC, et al. Radiological evidence of progression of bronchiectasis. Respir Med. 1992;86:397–401.
   PubMed Web of Science ®Google Scholar
• Altenburg J, Wortel K, van Der Werf TS, et al. Non-cystic fibrosis bronchiectasis: clinical presentation, diagnosis and treatment, illustrated by data from a Dutch teaching hospital. Neth J Med. 2015;73:147–154.
   PubMed Web of Science ®Google Scholar
• Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50:1700629.
   PubMed Web of Science ®Google Scholar
• Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med. 2013;368:1963–1970.
   PubMed Web of Science ®Google Scholar
• Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine. 2005;12:205–209.
   Google Scholar
• Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012;142:432–439.
   PubMed Web of Science ®Google Scholar
• Quittner AL, Modi AC, Watrous M, et al. Cystic Fibrosis Questionnaire - revised, version 2.0. 2000 [Accessed 2017 Feb 20]. Available from: www.psy.miami.edu/cfq-Qlab.
   Google Scholar
• Quittner AL, Marciel KK, Barker AF. Quality of Life Questionnaire - bronchiectasis, version 3.1; 2012 [cited 2017 Feb 20]. Available from: www.psy.miami.edu/cfq-Qlab.
   Google Scholar
• Quittner AL, Marciel KK, Salathe MA, et al. A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis. Chest. 2014;146:437–448.
   PubMed Web of Science ®Google Scholar
• Quittner AL, O’Donnell AE, Salathe MA, et al. Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax. 2015;70:12–20.
   PubMed Web of Science ®Google Scholar
• Quittner AL, Sawicki GS, McMullen A, et al. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res. 2012;21:1267–1278.
   PubMed Web of Science ®Google Scholar
• Grimwood K, Bell SC, Chang AB. Antimicrobial treatment of non-cystic fibrosis bronchiectasis. Expert Rev Anti Infect Ther. 2014;12:1277–1296.
   PubMed Web of Science ®Google Scholar
• Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chron Respir Dis. 2017;14:377–384.
   PubMed Web of Science ®Google Scholar
• Quint JK, Millett ER, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016;47:186–193.
   PubMed Web of Science ®Google Scholar
• Joish VN, Spilsbury-Cantalupo M, Operschall E, et al. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy. 2013;11:299–304.
   PubMedGoogle Scholar
• Blanchette CM, Noone JM, Stone G, et al. Healthcare cost and utilization before and after diagnosis of pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the U.S. Med Sci (Basel). 2017;5:E20.
   PubMedGoogle Scholar
• Hodson ME, Penketh AR, Batten JC. Aerosol carbenicillin and gentamicin treatment of pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet. 1981;2:1137–1139.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Loebinger M, Aliberti S. Challenges in the development of new therapies for bronchiectasis. Expert Opin Pharmacother. 2015;16:833–850.
   PubMed Web of Science ®Google Scholar
• King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med. 2006;100:2183–2189.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Sethi S. Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults. NPJ Prim Care Respir Med. 2017;27:18.
   PubMed Web of Science ®Google Scholar
• Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group. N Engl J Med. 1994;331:637–642.
   PubMed Web of Science ®Google Scholar
• Bilton D, Canny G, Conway S, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros. 2011;10:S79–S81.
   PubMed Web of Science ®Google Scholar
• Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017;49:1700051.
   PubMed Web of Science ®Google Scholar
• Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J. 2010;86:493–501.
   PubMed Web of Science ®Google Scholar
• Nicotra MB, Rivera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest. 1995;108:955–961.
   PubMed Web of Science ®Google Scholar
• Wilson CB, Jones PW, O’Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J. 1997;10:1754–1760.
   PubMed Web of Science ®Google Scholar
• King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med. 2007;101:1633–1638.
   PubMed Web of Science ®Google Scholar
• Borekci S, Halis AN, Aygun G, et al. Bacterial colonization and associated factors in patients with bronchiectasis. Ann Thorac Med. 2016;11:55–59.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Gao YH, Xu G, et al. Effect of airway pseudomonas aeruginosa isolation and infection on steady-state bronchiectasis in Guangzhou, China. J Thorac Dis. 2015;7:625–636.
   PubMed Web of Science ®Google Scholar
• Angrill J, Agustí C, De Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002;57:15–19.
   PubMed Web of Science ®Google Scholar
• Mao B, Lu HW, Li MH, et al. The existence of bronchiectasis predicts worse prognosis in patients with COPD. Sci Rep. 2015;5:10961.
   PubMed Web of Science ®Google Scholar
• Rogers GB, Zain NM, Bruce KD, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc. 2014;11:496–503.
   PubMedGoogle Scholar
• McShane PJ, Naureckas ET, Tino G, et al. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188:647–656.
   PubMed Web of Science ®Google Scholar
• Lee AL, Hill CJ, Cecins N, et al. The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis–a randomised controlled trial. Respir Res. 2014;15:44.
   PubMed Web of Science ®Google Scholar
• Newall C, Stockley RA, Hill SL. Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax. 2005;60:943–948.
   PubMed Web of Science ®Google Scholar
• Lee AL, Burge AT, Holland AE. Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev. 2017;9:CD011699.
   PubMedGoogle Scholar
• Lee AL, Williamson HC, Lorensini S, et al. The effects of oscillating positive expiratory pressure therapy in adults with stable non-cystic fibrosis bronchiectasis: a systematic review. Chron Respir Dis. 2015;12:36–46.
   PubMed Web of Science ®Google Scholar
• Lee AL, Burge AT, Holland AE. Airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev. 2015;11:CD008351.
   PubMed Web of Science ®Google Scholar
• Snijders D, Fernandez Dominguez B, Calgaro S, et al. Mucociliary clearance techniques for treating non-cystic fibrosis bronchiectasis: is there evidence? Int J Immunopathol Pharmacol. 2015;28:150–159.
   PubMed Web of Science ®Google Scholar
• Hassan JA, Saadiah S, Roslan H, et al. Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis. Respirology. 1999;4:423–426.
   PubMedGoogle Scholar
• O’Donnell AE, Barker AF, Ilowite JS, et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest. 1998;113:1329–1334.
   Google Scholar
• Tarrant BJ, Le Maitre C, Romero L, et al. Mucoactive agents for chronic, non-cystic fibrosis lung disease: a systematic review and meta-analysis. Respirology. 2017;22:1084–1092.
   PubMed Web of Science ®Google Scholar
• Wilkinson M, Sugumar K, Milan SJ, et al. Mucolytics for bronchiectasis. Cochrane Database Syst Rev. 2014;5:CD001289.
   PubMed Web of Science ®Google Scholar
• Fan LC, Liang S, Lu HW, et al. Efficiency and safety of surgical intervention to patients with non-cystic fibrosis bronchiectasis: a meta-analysis. Sci Rep. 2015;5:17382.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008;31:742–750.
   PubMed Web of Science ®Google Scholar
• Smith MP, Hill AT. Evaluating success of therapy for bronchiectasis: what end points to use? Clin Chest Med. 2012;33:329–349.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, McDonnell MJ, Rutherford R, et al. The generalizability of bronchiectasis randomized controlled trials: a multicentre cohort study. Respir Med. 2016;112:51–58.
   PubMed Web of Science ®Google Scholar
• Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014;2:738–749.
   PubMed Web of Science ®Google Scholar
• Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000;162:481–485.
   PubMed Web of Science ®Google Scholar
• Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of pseudomonas aeruginosa infection in adult bronchiectasis. Chest. 2006;130:1503–1510.
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013;68:812–817.
   PubMed Web of Science ®Google Scholar
• Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189:975–982.
   PubMed Web of Science ®Google Scholar
• Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183:491–499.
   PubMed Web of Science ®Google Scholar
• Drobnic ME, Suñé P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with pseudomonas aeruginosa. Ann Pharmacother. 2005;39:39–44.
   PubMed Web of Science ®Google Scholar
• Orriols R, Roig J, Ferrer J, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by pseudomonas aeruginosa. Respir Med. 1999;93:476–480.
   PubMed Web of Science ®Google Scholar
• Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2013;41:1107–1115.
   PubMed Web of Science ®Google Scholar
• Angrill J, Agusti C, De Celis R, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med. 2001;164:1628–1632.
   PubMed Web of Science ®Google Scholar
• Olivier KN, Shaw PA, Glaser TS, et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc. 2014;11:30–35.
   PubMedGoogle Scholar
• Hsieh MH, Fang YF, Chen GY, et al. The role of the high-sensitivity C-reactive protein in patients with stable non-cystic fibrosis bronchiectasis. Pulm Med. 2013;2013:795140.
   PubMedGoogle Scholar
• Coban H, Gungen AC. Is there a correlation between new scoring systems and systemic inflammation in stable bronchiectasis? Can Respir J. 2017;2017:9874068.
   PubMedGoogle Scholar
• Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189:576–585.
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, De Gracia J, Relat MV, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. 2014;43:1357–1367.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Aliberti S, Filonenko A, et al. Characterization of the “frequent exacerbator phenotype” in bronchiectasis. Am J Respir Crit Care Med. 2018;197:1410–1420.
   PubMed Web of Science ®Google Scholar
• Haworth C, Wanner A, Froehlich J, et al. Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic pseudomonas aeruginosa infection: results from two parallel phase III trials (ORBIT-3 and ORBIT-4). 2nd World Bronchiectasis Conference, 2017 July 6–8; Milan, Italy.
   Google Scholar
• Haworth CS, Wanner A, Froelich J, et al. Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic pseudomonas aeruginosa infection: results from two parallel phase III trials (ORBIT-3 and −4) [Abstract]. Am J Respir Crit Care Med. 2017;195:A7604.
   Web of Science ®Google Scholar
• De Soyza A, Aksamit T, Bandel TJ, et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018;51:1702052.
   PubMed Web of Science ®Google Scholar
• Aksamit T, De Soyza A, Bandel TJ, et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018;51:1702053.
   PubMed Web of Science ®Google Scholar
• Murray MP, Turnbull K, MacQuarrie S, et al. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009;34:125–131.
   PubMed Web of Science ®Google Scholar
• Olveira C, Olveira G, Gaspar I, et al. Depression and anxiety symptoms in bronchiectasis: associations with health-related quality of life. Qual Life Res. 2013;22:597–605.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Gao YH, Xu G, et al. Inflammatory responses, spirometry, and quality of life in subjects with bronchiectasis exacerbations. Respir Care. 2015;60:1180–1189.
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321–1327.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), et al. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims; 2009 [cited 2017 Oct 27]. Available from: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm193282.pdf.
   Google Scholar
• European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products; 2005 [cited 2017 Oct 27]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf.
   Google Scholar
• Spinou A, Siegert RJ, Guan WJ, et al. The development and validation of the Bronchiectasis Health Questionnaire. Eur Respir J. 2017;49:1601532.
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648–654.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Gao YH, Xu G, et al. Characterization of lung function impairment in adults with bronchiectasis. PLoS ONE. 2014;9:e113373.
   PubMed Web of Science ®Google Scholar
• McDonnell MJ, Aliberti S, Goeminne PC, et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax. 2016;71:1110–1118.
   PubMed Web of Science ®Google Scholar
• Araújo D, Shteinberg M, Aliberti S, et al. The independent contribution of pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J. 2018;51:1701953.
   PubMed Web of Science ®Google Scholar
• Chotirmall SH, Chalmers JD. RESPIRE: breathing new life into bronchiectasis. Eur Respir J. 2018;51:1702444.
   PubMed Web of Science ®Google Scholar
• Aradigm. Aradigm reports results of FDA advisory committee meeting on Linhaliq; 2018 cited 2018 Jan 11. Available from: https://globenewswire.com/news-release/2018/01/11/1287682/0/en/Aradigm-Reports-Results-of-FDA-Advisory-Committee-Meeting-on-Linhaliq.html.
   Google Scholar
• Aradigm. Aradigm receives complete response letter from the FDA for Linhaliq NDA; 2018 [cited 2018 Jan 29]. Available from: https://aradigm.gcs-web.com/news-releases/news-release-details/aradigm-receives-complete-response-letter-fda-linhaliq-nda.
   Google Scholar
• Chalmers JD, Crichton M, Goeminne PC, et al. The European multicentre bronchiectasis audit and research collaboration (EMBARC): experiences from a successful ERS clinical research collaboration. Breathe (Sheff). 2017;13:180–192.
   PubMedGoogle Scholar
• Chalmers JD, Aliberti S, Polverino E, et al. The EMBARC European bronchiectasis registry: protocol for an international observational study. ERJ Open Res. 2016;2:00081–2015.
   PubMedGoogle Scholar
• Aksamit TR, O’Donnell AE, Barker A, et al. Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. Chest. 2017;151:982–992.
   PubMed Web of Science ®Google Scholar
• Olveira C, Padilla A, M-Gm Á, et al. Etiology of bronchiectasis in a cohort of 2047 patients. An analysis of the Spanish historical bronchiectasis registry. Arch Bronconeumol. 2017;53:366–374.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Chotirmall SH. Bronchiectasis: new therapies and new perspectives. Lancet Respir Med. 2018. S2213-600(18)30053–5.
   PubMedGoogle Scholar
• Chen CL, Huang Y, Gao YH, et al. Inhaled medication therapy for bronchiectasis: status quo and the next frontier. Expert Opin Investig Drugs. 2018;27:211–218.
   PubMed Web of Science ®Google Scholar